2. Search Result
Search Result
Results for "

inhibits spontaneous locomotor activity

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113357
    m-Coumaric acid

    		Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
    m-Coumaric acid
  • HY-W015616
    Benzylacetone

    4-Penylbutan-2-one

    		 Environmental Pollutants Tyrosinase Infection Metabolic Disease
    Benzylacetone (4-Penylbutan-2-one) is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC50 of 2.8 mM, a Ki of 1.25 mM for monophenolase and an IC50 of 0.6 mM, a Ki of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .
    Benzylacetone
  • HY-113357R
    m-Coumaric acid (Standard)

    		Reference Standards Endogenous Metabolite Neurological Disease Inflammation/Immunology
    m-Coumaric acid (Standard) is the analytical standard of m-Coumaric acid. This product is intended for research and analytical applications. m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
    m-Coumaric acid (Standard)
  • HY-118402
    PD 119819

    		Dopamine Receptor Neurological Disease
    PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis .
    PD 119819
  • HY-121775
    PF-00217830

    		Dopamine Receptor Neurological Disease
    F-00217830 is an agonist ofDopamine D2 receptor. PF-00217830 inhibits of spontaneous locomotor activity and 2,5-dimethoxy-4-iodoamphetamine-induced head twitches in rats .
    PF-00217830
  • HY-118461
    PD 120697

    		Dopamine Receptor Neurological Disease
    PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .
    PD 120697
  • HY-183428
    LK00764

    		Trace Amine-associated Receptor (TAAR) Neurological Disease
    LK00764 is a TAAR1 agonist with an EC50 of 4 nM. LK00764 alleviates Dizocilpine (HY-15084B)-induced hyperlocomotion, reduces vertical locomotor activity, attenuates spontaneous hyperlocomotion in dopamine transporter knockout rats, and inhibits stress-induced hyperthermia in rats. LK00764 can be used for the research of schizophrenia .
    LK00764
  • HY-142110
    LY 78335

    DCMB

    		 Amine N-methyltransferase Adrenergic Receptor Neurological Disease
    LY 78335 (DCMB) is a brain-penetrant phenylethanolamine-N-methyltransferase (PNMT) inhibitor with a Ki of 0.09 μM. LY 78335 acts as an α₂-adrenoceptor inhibitor with an IC50 of 10 μM. LY 78335 increases spontaneous locomotor activity in rats. LY 78335 increases extracellular concentration of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rat hypothalamus. LY 78335 prevents growth hormone (GH) secretion in rats. LY 78335 can be used for the research of depression .
    LY 78335
  • HY-W015616R
    Benzylacetone (Standard)

    4-Penylbutan-2-one (Standard)

    		 Tyrosinase Reference Standards Infection Metabolic Disease
    Benzylacetone (4-Penylbutan-2-one) (Standard) is the analytical standard of Benzylacetone (HY-W015616). This product is intended for research and analytical applications. Benzylacetone is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC50 of 2.8 mM, a Ki of 1.25 mM for monophenolase and an IC50 of 0.6 mM, a Ki of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .
    Benzylacetone (Standard)
  • HY-15080
    GYKI 53405

    LY 293606

    		 iGluR Cardiovascular Disease Neurological Disease
    GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
    GYKI 53405
  • HY-182677
    EF-7412

    		5-HT Receptor Dopamine Receptor Neurological Disease
    EF-7412 is a dual antagonist of the 5-HT1A receptor and dopamine D2 receptor, with Ki values of 27 nM and 22 nM, respectively. EF-7412 acts as an antagonist at both pre- and postsynaptic 5-HT1A receptor sites, blocking 8-OH-DPAT (HY-112061)-induced hypothermia, behavioral syndrome, and corticosterone elevation in vivo. EF-7412 increases hypothalamic 5-HIAA/5-HT and DOPAC/DA ratios, alters 5-HT and DA neuronal activity, and slightly decreases spontaneous motor activity. EF-7412 can be used for research on 5-HT1A/D2 receptor regulation and related neural pathways .
    EF-7412

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: